Description: MedMira Inc. is a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and the Miriad triple product for preliminary screening of HIV and hepatitis. It also provides the Miriad RVF toolkit for rapid diagnostics development and Reveal G4 HIV tests. Additionally, the company offers the VYRATM TriDemic antigen rapid test, which distinguishes between three respiratory viruses. The company distributes its products through a network of medical distributors and strategic business development partners, serving customers in various healthcare sectors, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
Home Page: www.medmira.com
155 Chain Lake Drive
Halifax,
NS
B3S 1B3
Canada
Phone:
902 450 1588
Officers
| Name | Title |
|---|---|
| Mr. Hermes Chan | Co-Founder, CEO, President & Director |
| Mr. Markus M. Meile | Chief Financial Officer |
| Dr. Sam Ratnam | Director of Scientific & Regulatory Affairs |
| Stewart McKelvey | Legal Counsel |
| Dr. Kevin D. Jones | Head of Commercialization and Senior Director of Sales & Marketing |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 98.9914 |
| IPO Date: | |
| Fiscal Year End: | July |
| Full Time Employees: | 0 |